Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised phase III clinical study

Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, Vijay Yerroju, Rammohan Mogulla, Pothakamuri Venkata Suneetha, Kishore Turaga, Akshay Binayke, Aymaan Zaheer, Amit Awasthi, Rashmi Virkar, Manish Narang, Pradeep Nanjappa, Niranjana Mahantshetti, BishanSwarup Garg, Mandal RavindraNath Ravi
doi: https://doi.org/10.1101/2022.12.29.22284049

Data Availability

Study data presented in the manuscript can be made available upon request and addressed to the corresponding author Dr. Subhash Thuluva at his email: subhash.thuluva{at}biologicale.com.

Back to top
Posted January 03, 2023.
Download PDF
Data/Code
Email
Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised phase III clinical study
Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, Vijay Yerroju, Rammohan Mogulla, Pothakamuri Venkata Suneetha, Kishore Turaga, Akshay Binayke, Aymaan Zaheer, Amit Awasthi, Rashmi Virkar, Manish Narang, Pradeep Nanjappa, Niranjana Mahantshetti, BishanSwarup Garg, Mandal RavindraNath Ravi
medRxiv 2022.12.29.22284049; doi: https://doi.org/10.1101/2022.12.29.22284049
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area